Clinical stage biotechnology firm Ambrx closes $45m round of financing
Also participating in this round were Sinopharm Capital, Humanwell Healthcare Fund. Existing investors Fosun Pharma, HOPU Investments and Everbright Limited Healthcare Fund participated in the financing. The Company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.